Modern approach to the choice of laxative agent in surgical interventions in outpatient coloproctology

Introduction. Elimination of manifestations of functional constipation and normalization of the stool to date remain a complex and finally unresolved problem during typical surgical interventions in outpatient coloproctology.

Aim. To evaluate the clinical efficacy of the laxative agent sodium picosulfate in the surgical treatment of non-tumor diseases of the anal canal and rectum in outpatient settings.

Materials and methods. The results of surgical treatment of 566 patients with non-tumor diseases of the anal canal and rectum, which were divided into two groups, were analyzed. In 275 patients (group 1), laxative agents were not used during treatment or were used indiscriminately. In 291 patients (group 2), the laxative agent sodium picosulfate was used to normalize colon emptying and soften stools during treatment. Comparison criteria: level of pain syndrome after surgery, degree of inflammatory manifestations in the field of surgical intervention, shape, and nature of fecal masses (based on the Bristol scale), frequency of wound inflammatory complications and recovery time for patients.

Results. In the early stages after surgery, the stool had a softened consistency (type 5 and 6) in a much larger number of group 2 patients (89.7 ± 4.1 – 94.2 ± 5.1%) compared with group 1 patients (67.3 ± 4.8 – 76.7 ± 4.9%). At the same time, in group 2 patients, pain syndrome was less pronounced, inflammatory manifestations in the area of surgical intervention regressed faster, incidence of wound inflammatory complications decreased 2.8 times (from 16.4 to 5.8%) and work capacity was recovered earlier than in group 1 patients.

Conclusion. The use of the laxative agent sodium picosulfate in coloproctological patients when performing typical surgical interventions on the rectum and anal canal on an outpatient basis eliminates the manifestations of symptomatic constipation, ensures the formation of a softened stool in perioperative periods, reduces mechanical injury to the mucous membrane of the rectum by feces, reduces the level of pain syndrome, which improves the results of surgical treatment by reducing the number of wound inflammatory complications.

1. Lewis M.L., Palsson O.S., Whitehead W.E., van Tilburg M.A.L. Prevalence of Functional Gastrointestinal Disorders in Children and Adolescents. J Pediatr. 2016;177:39–43.e3. https://doi.org/10.1016/j.jpeds.2016.04.008.

2. Suares N.C., Ford A.C. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and metaanalysis. Am J Gastroenterol. 2011;106(9):1582–1591. https://doi.org/10.1038/ajg.2011.164.

3. Lazebnik L.B., Prilepskaya S.I., Baryshnikov E.N., Parfenov A.I., Kosacheva T.N. The prevalence and risk factors of constipation in the adult population of Moscow (according to the population study “MUZA”). Experimental and Clinical Gastroenterology. 2011;(3):68–73. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=15631766.

4. Samsonov A.A., Kucheryavy Yu.A., Andreev D.N. Chronic constipation: problems of therapy. Vrach. 2011;(4):24–29. (In Russ.) Available at: http://gastro.rusvrach.ru/archive/vrach-2011-04-06.pdf.

5. Bordin D.S., Kucheryavy Yu.A., Andreev D.N. Chronic constipation: the relevance of the problem and modern possibilities of therapy. Effective Pharmacotherapy. 2019;15(36):76–80. (In Russ.) https://doi.org/10.33978/2307-3586-2019-15-36-76-80.

6. Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;150(6):1393–1407.E5. https://doi.org/10.1053/j.gastro.2016.02.031.

7. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491. https://doi.org/10.1053/j.gastro.2005.11.061.

8. Belik B.M., Kovalev A.N. Experience of homeopathic ointment during the non-surgical treatment for acute hemorrhoids in the outpatient settings. Ambulatornaya Khirurgiya. 2022;19(1):98–106. (In Russ.) https://doi.org/10.21518/1995-1477-2022-19-1-98-106.

9. Maev I.V., Kazyulin A.N., Kucheryavy Yu.A., Cheryomushkin S.V., Goncharenko A.Yu., Gilyuk А.V. Diagnosis of Functional Gastrointestinal Disorders and Choice of Treatment Regimen in Constipation Patients. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(3):7–16. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-3-7-16.

10. Belik B.M., Kovalev A.N., Khatlamadzhiyan A.L. Administration of phlebotropic drugs during complex treatment of acute hemorrhoids. Koloproktologia. 2018;(2):48–53. (In Russ.) https://doi.org/10.33878/2073-7556-2018-0-2-48-53.

11. Shelygin Yu.A., Frolov S.A., Titov A.Yu., Blagodarny L.A., Vasilyev S.V., Veselov A.V. et al. The Russian association of coloproctology clinical guidelines for the diagnosis and treatment of hemorrhoids. Koloproktologia. 2019;18(1):7–38. (In Russ.) https://doi.org/10.33878/20737556-2019-18-1-7-38.

12. Belik B.M., Kovalev A.N. The use of autologous platelet-rich plasma in the complex treatment of anal fissure combined with anal sphincter spasm in non-hospital settings. Koloproktologia. 2022;21(1):50–59. (In Russ.) https://doi.org/10.33878/2073-7556-2022-21-1-50-58.

13. Drossman D.A., Hasler W.L. Rome IV – Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257–1261. https://doi.org/10.1053/j.gastro.2016.03.035.

14. Bharucha A.E., Lacy B.E. Mechanisms, Evaluation, and Management of Chronic Constipation. Gastroenterology. 2020;158(5):1232–1249.e3. https://doi.org/10.1053/j.gastro.2019.12.034.

15. Wald A., Sigurdsson L. Quality of life in children and adults with constipation. Best Pract Res Clin Gastroenterol. 2011;25(1):19–27. https://doi.org/10.1016/j.bpg.2010.12.004.

16. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Trukhmanov A.S., Poluektova E.A., Baranskaya E.K. et al. Diagnostics and treatment of chronic constipation in adults: clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(3):75–83. (In Russ.) Available at: https://www.gastro-j.ru/jour/article/view/160.

17. Ford A.C., Moayyedi P., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R. et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl. 1):S2–26. https://doi.org/10.1038/ajg.2014.187.

18. Lindberg G., Hamid S.S., Malfertheiner P., Thomsen O.O., Fernandez L.B., Garisch J. et al. World Gastroenterology Organisation global guideline: Constipation – a global perspective. J Clin Gastroenterol. 2011;45(6):483–487. https://doi.org/10.1097/MCG.0b013e31820fb914.

19. Forootan M., Bagheri N., Darvishi M. Chronic constipation: A review of literature. Medicine (Baltimore). 2018;97(20):e10631. https://doi.org/10.1097/MD.0000000000010631.

20. Daniali M., Nikfar S., Abdollahi M. An overview of interventions for constipation in adults. Expert Rev Gastroenterol Hepatol. 2020;14(8):721–732. https://doi.org/10.1080/17474124.2020.1781617.

21. Mueller-Lissner S., Kamm M.A., Wald A., Hinkel U., Koehler U., Richter E., Bubeck J. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105(4):897–903. https://doi.org/10.1038/ajg.2010.41.

22. Friedrich C., Richter E., Trommeshauser D., de Kruif S., van Iersel T., Mandel K., Gessner U. Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women. Drug Metab Pharmacokinet. 2011;26(5):458–464. https://doi.org/10.2133/dmpk.dmpk-11-rg-007.

23. Kienzle-Horn S., Vix J.M., Schuijt C., Peil H., Jordan C.C., Kamm M.A. Comparison of bisacodyl and sodium picosulphate in the treatment of chronic constipation. Curr Med Res Opin. 2007;23(4):691–699. https://doi.org/10.1185/030079907x178865.

24. Noergaard M., Traerup Andersen J., Jimenez-Solem E., Bring Christensen M. Long term treatment with stimulant laxatives – clinical evidence for effectiveness and safety? Scand J Gastroenterol. 2019;54(1):27–34. https://doi.org/10.1080/00365521.2018.1563806.

25. Nelson A.D., Camilleri M., Chirapongsathorn S., Vijayvargiya P., Valentin N., Shin A. et al. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut. 2017;66(9):1611–1622. https://doi.org/10.1136/gutjnl-2016-311835.

26. Corsetti M., Landes S., Lange R. Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation. Neurogastroenterol Motil. 2021;33(10):e14123. https://doi.org/10.1111/nmo.14123.

27. Krueger D., Demir I.E., Ceyhan G.O., Zeller F., Schemann M. Bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM)-the active metabolite of the laxatives bisacodyl and sodium picosulfate-enhances contractility and secretion in human intestine in vitro. Neurogastroenterol Motil. 2018;30(7):e13311. https://doi.org/10.1111/nmo.13311.

28. Drozdov V.N., Karnoukh K.I., Serebrova S.Yu., Komissarenko I.A., Starodubtsev A.K. Possibilities of sodium picosulfate application in constipation pharmacotherapy in functional intestinal disorders. Meditsinskiy Sovet. 2019;(3):92–97. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-92-97.

29. Ivashkin V.T., Maev I.V., Shelygin Yu.A., Baranskaya E.K., Belous S.S., Belousova E.A. et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74–95. (In Russ.) https://doi.org/10.22416/1382-43762021-31-5-74-95.